iCAD Corp - ICAD Company Value to Revenue Ratio

iCAD Inc. (ICAD) - corporate logo

iCAD, Inc. (ICAD) develops intelligent systems for the early diagnosis of breast cancer tailored for clinics and radiology centers. The company's price-to-sales ratio clearly demonstrates market expectations, with the current value of the indicator standing at . The business generates revenue through the sale of mammogram analysis software, while its growth strategy relies on organic SaaS development and the integration of algorithms into equipment from tomograph manufacturers.

iCAD Inc. - ICAD EV/Sales Multiple (period 07/04/2022 - 11/20/2026)

iCAD - analytical breakdowns and key metrics (ICAD)

- current quotes and average value forecast:
Fundamental valuation:ICAD (iCAD Inc.)
Finished products of icadmed.com

The EV/Sales metric determines the enterprise value of a business, including debt and excluding cash, relative to annual revenue, allowing investors to assess the premium paid per unit of revenue against market norms. The EV/Sales trend reflects the capitalization of iCAD, Inc. (ICAD) innovations in AI cancer diagnostics, where the efficiency of cloud architecture and ESG standards determine valuation sustainability and the risk of a price correction.

Competitor analysis for iCAD, Inc.

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|Enterprise Value-to-Revenue Multiple SELLAS Life Sciences Group SLS|EV/Sales Multiple ACTU|CTOR - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple HURA (TuHURA Biosciences, Inc.)|Business Value to Revenue TARA|FATE: Company Value to Revenue|WHWK (aadibio.com) - Company Value to Revenue Ratio|TCRX (TScan Therapeutics, Inc.) - Company Value to Revenue|Enterprise Value-to-Revenue Multiple Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - EV/Sales Multiple|CVM (CEL-SCI Corporation) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple OSTX|EV/Sales Multiple Radiopharm Theranostics Ltd (RADX)|EV/Sales Multiple ARTV (Artiva Biotherapeutics)|EV/Sales Multiple Adlai Nortye Ltd. ANL|Veru Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Tempest Therapeutics TPST|XLO: EV/Sales Multiple|Enochian BioSciences (RENB) - EV/Sales Multiple|Company Value to Revenue MURA|Kairos Pharma Ltd - Enterprise Value to Sales Volume|EV/Sales Multiple OKUR|CytoMed Therapeutics Limited (GDTC) - Enterprise Value-to-Sales Ratio|EV/Sales Multiple CRIS (Curis, Inc.)|APLM: Company Value to Revenue Ratio|Tharimmune Corporation - EV/Sales Multiple|ADVB: Enterprise Value-to-Revenue Ratio|GNPX: EV/Sales Multiple|CLDI (Calidi Biotherapeutics Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Sunshine Biopharma, Inc.|EV/Sales Multiple xeneticbio.com|Enterprise Value-to-Revenue Ratio Salarius (SLRX)|Company Value to Revenue Purple Biotech PPBT|Enterprise Value-to-Revenue Ratio American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Enterprise Value-to-Revenue Multiple|Checkpoint Therapeutics Inc. - EV/Sales Multiple|Business Value to Revenue ELEV (Elevation Oncology)|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio